Study identifier:137-161
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Prospective, Open-Label, Observational Study Evaluating SYMLIN® (pramlintide acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes Following SYMLIN Introduction Into the Marketplace
Type 1 Diabetes Mellitus
-
No
pramlintide acetate
All
1297
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Feb 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace. Health care providers and subjects selected for study participation are intended to be representative of those providers prescribing, and subjects receiving, SYMLIN therapy.
Location
Location
Toledo, OH, United States
Location
Salinas, CA, United States
Location
Idaho Falls, ID, United States
Location
Baton Rouge, LA, United States
Location
Spokane, WA, United States
Location
Norwalk, CT, United States
Location
Moreno Valley, CA, United States
Location
Binghamton, NY, United States
Arms | Assigned Interventions |
---|---|
Type 1 Patients with type 1 diabetes | Drug: pramlintide acetate Subcutaneous injection prior to each major meal Other Name: Symlin |
Type 2 Patients with type 2 diabetes | Drug: pramlintide acetate Subcutaneous injection prior to each major meal Other Name: Symlin |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.